Only Oncotype DX Breast Recurrence Score has predictive and prognostic results you can count on for your early-invasive breast cancer patients

Genomic Health®
ONCOTYPE DX®
NanoString
PROSIGNA®
Agendia®
MAMMAPRINT®
bioTheranostics
BREAST CANCER INDEX™
Myriad
ENDOPREDICT®
Validated for
Prognosis1-6
Node Negative and Node Positive ✔︎ ✔︎ ✔︎ ✔︎ ✔︎
Pre-Menopausal ✔︎ ✔︎ ✔︎ ✔︎
Post-Menopausal ✔︎ ✔︎ ✔︎ ✔︎ ✔︎
Homogenous Populations ✔︎ ✔︎ ✔︎ ✔︎
Validated for prediction of Chemotherapy Benefit1 ✔︎
Inclusion in Major
International Guidelines*
NCCN® Algorithm7 and NICE (UK)8 ✔︎
NCCN Discussion Section7 ✔︎ ✔︎ ✔︎
ASCO®9 ✔︎ ✔︎ ✔︎
ESMO10, St. Gallen11 and AGO12 ✔︎ ✔︎ ✔︎ ✔︎
Prospective Outcomes Evidence >63,000 patients13-20 >7,000 patients21-24
Inclusion in AJCC 8th Ed. Cancer Staging Manual for assignment of Prognostic Stage Group 1A25 ✔︎
Additional Clinical Evidence DCIS, Neoadjuvant, Late Recurrence, Adjuvant Hormonal Therapy Benefit Neoadjuvant, Late Recurrence Neoadjuvant Late Recurrence, Adjuvant Hormonal Therapy Benefit Late Recurrence

SEE ONCOTYPE DX vs. MAMMAPRINT


REFERENCES

1. Bayt et al. St. Gallen 2015.
2. Markopoulos et al. Eur J Oncol. 2016.
3. Filipits et al. Clin Cancer Res. 2011.
4. Martin et al. Breast Cancer Research. 2014.
5. Sgroi et al. Lancet Oncol. 2013.
6. Zhang et al. Clin Cancer Res. 2013.
7. NCCNClinical Practice Guidelines in Oncology. V.2.2016.
8. NICE Diagnostics Guidance 10. 2013.
9. Harris et al. J Clin Oncol. 2016.
10. Senkus et al. Ann Oncol. 2015.
11. Coates et al. Ann Oncol. 2015.
12. www.ago-online.de Guidelines Breast Cancer Version 2016.1.
13. Sparano et al. N Engl J Med. 2015.
14. Petkov et al. npg Breast Cancer. 2016.
15. Shak et al. ASCO QCS 2016.
16. Gluz et al. J Clin Oncol. 2016.
17. Stemmer et al. SABCS 2015.
18. Stemmer et al. ESMO 2016.
19. Miller et al. ESMO 2016.
20. Shak et al. ESMO 2016.
21. Cardoso et al. N Engl J Med. 2016.
22. Drukker et al. Int J Cancer. 2013.
23. van de Vijver et al. N Engl J Med. 2002.
24. Buyse et al. J Natl Cancer Inst. 2006.
25. AJCC Cancer Staging Manual 8th edition 2017.

NCCN is a trademark of the National Comprehensive Cancer Network. ASCO is a trademark of the American Society of Clinical Oncology. AJCC is a trademark of the American College of Surgeons. NCCN, ASCO, ESMO, St. Gallen, NICE, AGO and AJCC do not endorse any product or therapy.

 

Next: Prospective Outcomes